TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
22 oct. 2023 10h30 HE
|
Genmab A/S
Media Release TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
17 oct. 2023 06h22 HE
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the third quarter of 2023 totaled USD 2,499 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
28 sept. 2023 14h38 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,609 restricted stock units and 7,873 warrants to employees...
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
25 sept. 2023 07h45 HE
|
Genmab A/S
Company Announcement TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large...
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
25 sept. 2023 05h55 HE
|
Genmab A/S
Media Release Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
12 sept. 2023 14h04 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 12, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,356 shares as a consequence of the exercise of employee warrants. ...
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
04 sept. 2023 15h00 HE
|
Genmab A/S
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for...
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
28 août 2023 10h06 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
15 août 2023 13h09 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 15, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,700 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Financial Results for the First Half of 2023
03 août 2023 11h01 HE
|
Genmab A/S
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S....